ZIAC Drug Patent Profile
✉ Email this page to a colleague
When do Ziac patents expire, and when can generic versions of Ziac launch?
Ziac is a drug marketed by Teva Branded Pharm and is included in one NDA.
The generic ingredient in ZIAC is bisoprolol fumarate; hydrochlorothiazide. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the bisoprolol fumarate; hydrochlorothiazide profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Ziac
A generic version of ZIAC was approved as bisoprolol fumarate; hydrochlorothiazide by EPIC PHARMA LLC on September 25th, 2000.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZIAC?
- What are the global sales for ZIAC?
- What is Average Wholesale Price for ZIAC?
Summary for ZIAC
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 131 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for ZIAC |
| What excipients (inactive ingredients) are in ZIAC? | ZIAC excipients list |
| DailyMed Link: | ZIAC at DailyMed |
Pharmacology for ZIAC
| Drug Class | Thiazide Diuretic beta-Adrenergic Blocker |
| Mechanism of Action | Adrenergic beta-Antagonists |
| Physiological Effect | Increased Diuresis |
US Patents and Regulatory Information for ZIAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-003 | Mar 26, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-001 | Mar 26, 1993 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-002 | Mar 26, 1993 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ZIAC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-003 | Mar 26, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-001 | Mar 26, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-002 | Mar 26, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| Teva Branded Pharm | ZIAC | bisoprolol fumarate; hydrochlorothiazide | TABLET;ORAL | 020186-003 | Mar 26, 1993 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for ZIAC
See the table below for patents covering ZIAC around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | A717377 | ⤷ Sign Up | |
| South Africa | 7706018 | ⤷ Sign Up | |
| Yugoslavia | 40820 | ⤷ Sign Up | |
| France | 2367053 | ⤷ Sign Up | |
| Italy | 1091303 | FENOSSI-AMMINO-PROPANOLI E PROCEDIMENTO PER LA LORO PRODUZIONE | ⤷ Sign Up |
| Switzerland | 630337 | VERFAHREN ZUR HERSTELLUNG VON NEUEN 3-PHENOXY-2-HYDROXY-1-AMINOPROPANEN. | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
